OBJECTIVE: CCL23 [Ckβ8-1/myeloid progenitor inhibitory factor 1 (MPIF1)/macrophage inflammatory protein-3 (MIP3)], a member of the CC chemokine family, is involved in leukocyte trafficking, and implicated in inflammatory diseases. In the present study, we investigated the role of CCL23 in the development of human atherosclerosis, which is characterized by an inflammatory disease. METHODS: CCL23 transcripts were measured by reverse transcriptase-polymerase chain reaction (RT-PCR) and CCL23 protein by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). Expression of adhesion molecules was determined by flow cytometry, and matrix metalloproteinase-2 (MMP-2) levels by zymography. RESULTS: Proatherogenic factors such as oxidized low-density lipoprotein (oxLDL) and oxidative stress markedly enhanced CCL23 release from human THP-1 macrophages. CCL23 stimulated chemotaxis of human THP-1 monocytes in a dose-dependent manner and enhanced the expression of adhesion molecule CD11c, as well as release of MMP-2 from the THP-1 monocytes. Moreover, CCL23 expression at the mRNA level was significantly higher in human atherosclerotic lesions than in normal arteries, and CCL23 protein was co-expressed with CD68, a specific marker for macrophages. Circulating levels of plasma CCL23 were higher in atherosclerotic patients than in normal subjects. CONCLUSION: These findings suggest that CCL23 plays a role in the development of human atherosclerosis. CCL23 may be a useful target for the development of antiatherogenic agents.
OBJECTIVE:CCL23 [Ckβ8-1/myeloid progenitor inhibitory factor 1 (MPIF1)/macrophage inflammatory protein-3 (MIP3)], a member of the CC chemokine family, is involved in leukocyte trafficking, and implicated in inflammatory diseases. In the present study, we investigated the role of CCL23 in the development of humanatherosclerosis, which is characterized by an inflammatory disease. METHODS:CCL23 transcripts were measured by reverse transcriptase-polymerase chain reaction (RT-PCR) and CCL23 protein by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). Expression of adhesion molecules was determined by flow cytometry, and matrix metalloproteinase-2 (MMP-2) levels by zymography. RESULTS: Proatherogenic factors such as oxidized low-density lipoprotein (oxLDL) and oxidative stress markedly enhanced CCL23 release from humanTHP-1 macrophages. CCL23 stimulated chemotaxis of humanTHP-1 monocytes in a dose-dependent manner and enhanced the expression of adhesion molecule CD11c, as well as release of MMP-2 from the THP-1 monocytes. Moreover, CCL23 expression at the mRNA level was significantly higher in humanatherosclerotic lesions than in normal arteries, and CCL23 protein was co-expressed with CD68, a specific marker for macrophages. Circulating levels of plasma CCL23 were higher in atheroscleroticpatients than in normal subjects. CONCLUSION: These findings suggest that CCL23 plays a role in the development of humanatherosclerosis. CCL23 may be a useful target for the development of antiatherogenic agents.
Authors: A Matsumori; K Ono; R Nishio; H Igata; T Shioi; S Matsui; Y Furukawa; A Iwasaki; Y Nose; S Sasayama Journal: Circulation Date: 1997-09-02 Impact factor: 29.690
Authors: Leticia Castillo; Anand Rohatgi; Colby R Ayers; Andrew W Owens; Sandeep R Das; Amit Khera; Darren K McGuire; James A de Lemos Journal: J Interferon Cytokine Res Date: 2010-05 Impact factor: 2.607
Authors: Courtney K Domigan; Carmen M Warren; Vaspour Antanesian; Katharina Happel; Safiyyah Ziyad; Sunyoung Lee; Abigail Krall; Lewei Duan; Antoni X Torres-Collado; Lawrence W Castellani; David Elashoff; Heather R Christofk; Alexander M van der Bliek; Michael Potente; M Luisa Iruela-Arispe Journal: J Cell Sci Date: 2015-05-08 Impact factor: 5.285
Authors: Elena Schiopu; Karen M Au; Maureen A McMahon; Mariana J Kaplan; Anagha Divekar; Ram R Singh; Daniel E Furst; Philip J Clements; Nagesh Ragvendra; Wenpu Zhao; Paul Maranian; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2013-12-19 Impact factor: 7.580
Authors: Udai P Singh; Narendra P Singh; E Angela Murphy; Robert L Price; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti Journal: Cytokine Date: 2015-10-29 Impact factor: 3.861
Authors: Gulnaz F Korytina; Yulia G Aznabaeva; Leysan Z Akhmadishina; Olga V Kochetova; Timur R Nasibullin; Naufal Sh Zagidullin; Shamil Z Zagidullin; Tatyana V Viktorova Journal: Biochem Genet Date: 2021-06-06 Impact factor: 1.890
Authors: Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Kevin G McLure; Peter R Young; Allan Gordon; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C Wong Journal: Data Brief Date: 2016-07-29
Authors: Marc J George; Ola Kleveland; Jorge Garcia-Hernandez; Jutta Palmen; Ruth Lovering; Rune Wiseth; Pål Aukrust; Jorgen Engmann; Jan Kristian Damås; Aroon D Hingorani; Lars Gullestad; Juan P Casas; Thor Ueland Journal: J Am Heart Assoc Date: 2020-06-09 Impact factor: 5.501
Authors: Markus Sällman Almén; Jonas Björk; Ulf Nyman; Veronica Lindström; Magnus Jonsson; Magnus Abrahamson; AnnaLotta Schiller Vestergren; Örjan Lindhe; Gary Franklin; Anders Christensson; Anders Grubb Journal: Kidney Int Rep Date: 2018-09-13